Yonhap Infomax NewsViking Therapeutics shares plunged 42% after interim Phase 2 trial data for its oral obesity drug VK2735 revealed high dropout rates and side effects, disappointing investors despite comparable weight loss efficacy to competitors.
#YonhapInfomax #VikingTherapeutics #ObesityDrug #ClinicalTrial #DropoutRate #WeightLossEfficacy #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=77793
#YonhapInfomax #VikingTherapeutics #ObesityDrug #ClinicalTrial #DropoutRate #WeightLossEfficacy #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=77793
Viking Therapeutics Plunges 42% on Disappointing Obesity Drug Trial Results
Viking Therapeutics shares plunged 42% after interim Phase 2 trial data for its oral obesity drug VK2735 revealed high dropout rates and side effects, disappointing investors despite comparable weight loss efficacy to competitors.